New research suggests that people who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight far faster than those who stop traditional diet and exercise plans.
Research printed in a major medical journal points out that while overweight people can lose a large proportion of their body weight while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People using such drugs should be aware of the potential of rapid rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment mass within about 18 months.
Comparing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of patients, compared the results of the injectable medications with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally have a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Regain
Nutrition scientists believe the way of the injections explains the accelerated regain.
The injections imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
The NHS advise the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the high risk of relapse, the treatment should be considered life-long.
This opinion is supported by drug manufacturers, who note that the findings "emphasize the chronic nature of obesity," similar to managing conditions like high blood pressure.
Patient Accounts
Users who have discontinued the jabs explain a sudden resurgence of hunger.
"It was like a trigger that goes on and you become extremely hungry," recalled an individual.
This difficulty is exacerbated if patients have not established lasting dietary or behavioural modifications during treatment.
Widespread Interest
Survey data suggest that millions of people in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and long-term success relies on ongoing behavioural management.
